Short-Acting Benzodiazepines and Dosing
For insomnia treatment, the short-acting benzodiazepines triazolam (0.25 mg at bedtime) and temazepam (15-30 mg at bedtime) are the recommended agents, with dose reductions to 0.125 mg and 7.5 mg respectively in elderly or debilitated patients. 1, 2
Primary Short-Acting Benzodiazepines
The American Academy of Sleep Medicine guidelines identify these as the key short-acting benzodiazepines for clinical use:
Triazolam
- Standard dose: 0.25 mg at bedtime (maximum 0.5 mg)
- Elderly/debilitated: 0.125 mg at bedtime (maximum 0.25 mg)
- Half-life: 2-5 hours 3
- Primary indication: Sleep-onset insomnia 1, 2
- Onset: 2-5 minutes after IV administration 1
Temazepam
- Standard dose: 15-30 mg at bedtime
- Elderly/debilitated: 7.5 mg at bedtime
- Half-life: Short to intermediate-acting
- Primary indication: Both sleep-onset and sleep maintenance insomnia 1, 2
- Onset: 15-20 minutes 1
Clinical Context and Selection
When choosing between agents, match the drug's duration to the patient's specific insomnia pattern:
- Sleep-onset difficulty only: Triazolam is preferred due to its ultra-short half-life (2-5 hours), minimizing next-day residual effects 3, 4
- Sleep-onset plus maintenance issues: Temazepam provides longer coverage (8-10 hours) 5
- Elderly patients: Always start with the lower dose range due to increased sensitivity to benzodiazepine effects 6
Critical Dosing Principles
Start low and titrate cautiously - the guidelines emphasize using the lowest effective maintenance dosage 1:
- Administer on an empty stomach to maximize effectiveness 1
- Avoid doses exceeding the maximum recommendations
- In patients >75 years, consider 50% dose reduction 7
- Assess effectiveness after 2-4 weeks at stable dosing 1
Important Safety Considerations
These medications carry specific risks that require patient counseling:
- Respiratory depression - particularly when combined with opioids or other CNS depressants 1, 6
- Anterograde amnesia - dose-dependent effect 4
- Rebound insomnia - occurs on abrupt discontinuation, especially with short-acting agents 8, 9
- Falls risk - especially in elderly; short-acting agents have lower risk than long-acting benzodiazepines 9
- Sleep-related behaviors - sleepwalking, sleep-driving, sleep-eating have been reported 1
Contraindications and Cautions
Do not use or use with extreme caution in:
- Pregnancy or nursing 1
- Compromised respiratory function (asthma, COPD, sleep apnea) 1
- Hepatic or heart failure 1
- Patients <18 years (safety not established) 1
- Concurrent alcohol or CNS depressant use 1
Withdrawal and Discontinuation
Taper gradually to avoid withdrawal symptoms - abrupt discontinuation can produce rebound insomnia similar to barbiturate and alcohol withdrawal 1. The short-acting agents may show rebound insomnia within 1-2 nights of cessation 3, 9, but this is dose-dependent and can be minimized by tapering 9.
Reversal Agent
Flumazenil is available for benzodiazepine reversal:
- Dose: 0.01-0.02 mg/kg IV (maximum 0.2 mg), repeat at 1-minute intervals up to cumulative 0.05 mg/kg or 1 mg 10
- Caution: Duration of flumazenil is shorter than most benzodiazepines; observe for at least 2 hours after last dose 10
- Contraindication: Do not use in tricyclic antidepressant overdose or in patients with seizure disorders on chronic benzodiazepines 10